Other languages Innovent Biologics, Inc.

Equities

1801

KYG4818G1010

Market Closed - Hong Kong S.E. Other stock markets 04:08:22 2024-04-29 EDT			5-day change	1st Jan Change
39.75 ^HKD	+1.53%		+17.08%	-7.02%

04-17	Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	CI
04-02	Hutchmed endometrial cancer treatment application accepted for review	AN

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	04-16
Hutchmed endometrial cancer treatment application accepted for review	04-02
HSBC in special payout on Canada sale; Astra FDA win	04-02
Innovent Biologics New Cancer Drug Gets NDA from Chinese Authority	04-02
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	04-02
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application	04-02
Innovent Biologics' Loss Narrows in 2023 as Revenue Grows	03-20
Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024	03-06
China Accepts Innovent's Second Drug Application for Lung Cancer Treatment; Shares Slide 6%	03-05
Anheart Therapeutics and Innovent Announces China?s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer	03-04
Innovent Biologics' Phase 3 Trial for Thyroid Eye Disease Treatment Meets Primary Endpoints	02-19
Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease	02-19
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	02-15
Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee	02-09
Innovent Biologics’ New Drug Application for Weight Management Drug Accepted by Chinese Regulator	02-07
Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China	02-07
Innovent Biologics Posts 65% Revenue Growth in Q4 of 2023	02-06
Innovent Biologics Names New CFO	02-05
Innovent Bio's Weight Management Drug Trial Meets Primary and Secondary Endpoints	01-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Innovent Biologics, Inc.

Equities

1801

KYG4818G1010

Other languages

Filters